Human papilloma viruses and cancer in the post-vaccine era

Clinical Microbiology and Infection

Volumn 15, Issue 11, 2009, Pages 977-981

  Galani, E ^a   Christodoulou, C ^a  

^a METROPOLITAN HOSPITAL   (Greece)

Author keywords

Cancer; Cervical cancer; Human papillomavirus; Human papillomavirus related cancers; Review; Vaccines; Virus

Indexed keywords

VIRUS VACCINE;

ANUS CARCINOMA; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; DEVELOPING COUNTRY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 45; NONHUMAN; OROPHARYNX CARCINOMA; PREVALENCE; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX EPITHELIUM; WART VIRUS;

HUMAN PAPILLOMAVIRUS;

EID: 70449105202     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.03032.x     Document Type: Review

References (27)

1. Bosch FX. A scientific response to prevent cervical cancer in the world. Vaccine 2008, 26(suppl):v-vi.
2. zur Hausen H. Oncogenic herpes viruses. Biochim Biophys Acta 1974, 417:25-53.
3. zur Hausen H. Condylomata acuminate and human genital cancer. Cancer Res 1976, 36:794.
4. Meisels A, Fortin R. Condylomatus lesions of the cervix and vagina. Cytologic patterns. Acta Cytol 1976, 20:505-509.
5. zur Hausen H. Papilomavirus in the causation of human cancers - a brief historical account. Virol 2009, 384:260-265.
6. Bosch FX, Lorincz A, Munoz N, Meijer CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002, 55:244-265.
7. Lehtinen M, Paavonen J. Effectiveness of preventive human papillomavirus vaccination. Int J STD AIDS 2003, 14:787-792.
8. Castellsaque X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol 2008, 110:S4-S7.
9. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005, 32(suppl 1):S16-S24.
10. Munoz N, Castellsaque X, de Gonzalez AB, Gissmann L. HPV in the etiology of human cancer. Vaccine 2006, 24(suppl):S1-S10.
11. Munoz N, Bosch FX, de Sanjose S. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Eng J Med 2003, 348:518-527.
12. Madsen BS, Jensen HL, van den Brule AJ, Wohlfahrt J, Frisch M. Risk factors for invasive squamous cell carcinoma of the vulva and vagina-population based case control study in Denmark. Int J Cancer 2008, 122:2827-2834.
13. Bezerra AL, Lopes A, Santiago GH, Ribeiro KC, Latorre MR, Villa LL. Human papillomavirus as a prognostic factor in carcinoma of the penis: analysis of 82 patients treated with amputation and bilateral lymphadenectomy. Cancer 2001, 91:2315-2321.
14. Lont AP, Kroon BK, Horenblas S. Presence of high risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival. Int J Cancer 2006, 119:1078-1081.
15. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus in invasive cervical cancer worldwide: a meta-analyses. Br J Cancer 2003, 88:63-73.
16. von Krogh G. Management of anogenital warts. Eur J Dermatol 2001, 16:598-603.
17. Bosch FX, Sanjoze S. Chapter 1: human papillomavirus and cervical cancer-burden and assessment causality. J Natl Cancer Inst Monogr 2003, 31:3-31.
18. Herrero R, Hildesheim A, Bratti C. Population based study of human papillomavirus infection and cervical neoplasis in rural Costa Rica. J Natl Cancer Inst 2000, 92:464-474.
19. Janicek MF, Averette HE. Cervical cancer: prevention, diagnosis and therapeutics. CA Cancer J Clin 2001, 51:92-114.
20. Beaudenon S, Huibregtse MJ. HPV E6, E6AP and cervical cancer. BMC Biochem 2008, 9(suppl):S4.
21. Zhou JA, McIndoe A, Davies H, Sun XY, Crawford L. The induction of cytotoxic T-lymphocyte precursor cells by recombinant vaccinia expressing human papillomavirus type 16 L1. Virol 1991, 18:203-210.
22. Colgrove J. The ethics and politics of compulsory HPV vaccination. N Engl J Med 2006, 355:2389-2391.
23. Newall AT, Beutels P, Wood JG, Edmunds WJ, MacIntyre CR. Cost-effectiveness analyses of human papilomavirus vaccination. Lancet Infect Dis 2007, 7:289.
24. French KM, Barnabas RV, Lehtinen M. Strategies for the introduction of human papillomavirus vaccination: modeling the optimum age- and sex-specific pattern of vaccination in Finland. Br J Cancer 2007, 96:514-518.
25. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008, 359:821-832.
26. Munoz N, Manalastas R, Pitisuttithum P. Safety, immunogenicity and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomized, double-blind trial. Lancet 2009, 373:1949-1957.
27. Arbyn M, Dillner J. Review of current knowledge on HPV vaccine: an appendix to the European Guidelines for Quality Assurance in Cervical cancer screening. J Clin Virol 2007, 38:189-197.